Clin Osteol 2011; 16(1): 11-15

Advanced secondary hyperparathyroidism in renal failure - surgical or pharmacological therapy? - Report of two casesShort communications

M. Kubišová, R. Šafránek M. Ságová, J. Horáček, M. Podhola, S. Dusilová Sulková

The case report describes two different cases of chronic dialysis patients with secondary hyperparathyroidism, for each of whom a dif­ ferent type of therapy was selected. The first patient, despite a higher operative risk, underwent parathyroidectomy, selected mainly with respect to clinical problems. After the parathyroid glands were surgically removed, not only serum PTH levels returned to nor­ mal but many symptoms disappeared. In the other case, by contrast, long-term combined pharmacotherapy was sufficient to control serum calcium, phosphorus and PTH and the patient remained asymptomatic.

Keywords: secondary hyperparathyroidism, parathyroidectomy, renalfailure

Published: June 11, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kubišová M, Šafránek Ságová RM, Horáček J, Podhola M, Dusilová Sulková S. Advanced secondary hyperparathyroidism in renal failure - surgical or pharmacological therapy? - Report of two cases. Osteologický bulletin. 2011;16(1):11-15.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dusilová Sulková S a kol. Renální osteopatie. Maxdorf Jessenius 2007.
    2. Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Americanjournal ofphysiology. Am J Physiol Renal Physiol 2002;283: F367-F376. Go to original source...
    3. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-1953. Go to original source...
    4. Dusilová Sulková S. Kostní minerálová porucha při chronickém onemocnění led­ vin - přehled problematiky. Osteol Bull 2008;13:144-151.
    5. Kakuta T, Tanaka R, Kanai G, Sawaya A, Hirukawa T, Sato A, Saito A Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroi­ dism? Ther Apher Dial 2009;13 (Suppl 1):S20-27. Go to original source...
    6. Horáček J. Ultrazvukové vyšetření příštítných tělísek u chronických nemocí led­ vin. Osteologický bulletin 2008;13:152-155.
    7. Eren PA, Turan K, Berber I, Canbakan M, Kara M, Tellioglu G, Bugan U, Sevinc C, Turkmen F, Titiz MI. The clinical significance of parathyroid tissue calcium sensing receptor gene polymorphisms and expression levels in end-stage renal di­ sease patients. Clin Nephrol 2009;72:114-121.
    8. Cunningham J, Locatelli F, Rodriquez M. Secondary hyperparathyroidism: patho­ genesis, disease progression and therapeutic options. Clin J Am Soc Nephrol 2011;6:913-921. Go to original source...
    9. Barreto FC, Barreto DV, Liabeuf S, Drueke TB, Massy ZA et al: Effects of ure­ mic toxins on vascular and bone remodling. Semin Dial 2009;22:433-437. Go to original source...
    10. Rodriguez M, Lorenzo V. Prathyroid hormone, an uremic toxin. Semin Dial 2009;22:363-367. Go to original source...
    11. Drueke T, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistence of chronic renal failure patients. Nephrol Dial Transplant 2002; 17 (Suppl. 5):28-31. Go to original source...
    12. Noordzij M, Boeshoten E, Bos W, Dekker FW, Bosuyt PM, Kredit RT, Korevaar JC for the NECOSAD Study Group. Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patiens. Nephrol Dial Transplant 2007;22:2944-2949. Go to original source...
    13. Golan E, Haggiag I, Os P, Bernheim J. Calcium, parathyroid hormone and vita­ min D: major determinant of chronic pain in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:1374-1380. Go to original source...
    14. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialy­ sis patients with different levels of serum calcium, phosphorus and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-530. Go to original source...
    15. Floege J, Kim J, Ireland E, Chazot Ch, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC on be­ half of the ARO investigators. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2010; doi 10.1093/dnt/gfq219. Go to original source...
    16. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO® clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease - mineral bone disorder (CKD-MBD). Kidney Int 2009;76 (Suppl 113):S1-S130.
    17. National Kidney Foundation. K/DOQITM clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42 (suppl 3):S1-S201.
    18. Dusilová Sulková S, Opatrná S, Ryšavá R, Teplan V, Viklický O, Zahálková J. KDIGO doporučení pro diagnostiku a léčbu CKD-MBD: komentovaný návod pro klinickou praxi. Aktuality v nefrologii 2010;16:113-126.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.